<DOC>
	<DOCNO>NCT01919346</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Eculizumab prevention Delayed Graft Function follow decease donor kidney transplantation . Based experimental data supportive observation human associate complement gene upregulation ischemic reperfusion ( IR ) injury , hypothesize C5 cleavage key step pathogenesis ischemic reperfusion injury follow transplantation . It hypothesize Eculizumab , humanize monoclonal antibody block C5 cleavage human effective prophylactic agent prevent IR injury high risk recipient . This trial prospective , randomize study test efficacy eculizumab vs. placebo give time transplantation 24 hour later prevent delay graft function first adult recipient decease donor kidney .</brief_summary>
	<brief_title>Eculizumab Prevention Delayed Graft Function ( DGF ) Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>Age 18 year old Weight &gt; 40 kg Male Female Recipient first decease donor kidney Able provide write informed consent Transplant candidate per site specific guideline Dialysis dependent renal failure ( initiated 2 month prior transplant ) Recipients kidney define : 1 . Extended Criteria Donor ( ECD ) kidney brain death : Kidney donor 60 year age old ; donor aged 5059 year two follow feature : Hypertension , terminal serum creatinine &gt; 1.5 mg/dL , death cerebrovascular accident ( CVA ) , OR 2 . Standard Criteria Donor ( SCD ) kidney actual cold ischemia time ( CIT ) 18 40 hour Patient plan receive multiorgan transplant Kidney donor &lt; 6 year age Dual kidney transplant ( donor , include en bloc ) Living donor kidney transplant Recipients donorspecific antiHLA antibodies 3,000 MFI Participation another investigational drug study Recipient BMI &gt; 40 ABO incompatible DCD ( donor cardiac death ) Donor Women pregnant breastfeed Women child bear potential unable unwilling use medically acceptable form contraception ( define use oral , injected implant hormonal method contraception , intrauterine device ( IUD ) intrauterine system ( IUS ) , barrier method contraception ( condom occlusive cap spermicidal foam/gel/film/cream/suppository ) Patients HBsAgpositive status , HCV infection , HIV infection Patients atypical hemolytic uremic syndrome ( aHUS ) C3 glomerulonephritis ( C3GN ) Active bacterial infection clinically significant opinion investigator Patients history splenectomy Patients history meningococcal disease Patients allergic unable tolerate Ciprofloxacin Patients unable unwilling receive vaccination meningitis prior study drug administration Patients know suspect hereditary complement deficiency Patients history cancer ( non melanoma skin cancer ) within last five year Donors 70 year age Subjects psychiatric physical illness opinion Investigator would interfere ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Delayed Graft Function</keyword>
</DOC>